Payment overview · 2025
General Payments
$441.07
18 reported records · 10 companies
Healthcare provider profile · identity verified
Grace I Wong, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BURBANK, CA · NPI 1053504902
Verified facts
What the public records show
CMS Open Payments records show Grace I Wong, M.D. received $441.07 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.47 | 20.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.45 | 13.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.01 | 11.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.96 | 11.8% | 2 | 2025 |
| Dynasplint Systems Inc. | Unresolved — no canonical attribution shown | $51.11 | 11.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.78 | 7.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $30.02 | 6.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.79 | 6.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $26.93 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.55 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $441.07 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.45 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.01 | 2 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $51.96 | 2 | 2025 |
Source payment records
|
|||||
| Dynasplint Normalized: dynasplint |
Device | Dynasplint Systems Inc. | $51.11 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.78 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 291 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 49 |
| Gabapentin | Gabapentin | 156 | 41 |
| Metformin Hcl | Metformin Hcl | 147 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 42 |
| Lisinopril | Lisinopril | 127 | 32 |
| Losartan Potassium | Losartan Potassium | 106 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 29 |
| Eliquis | Apixaban | 81 | 25 |
| Ozempic | Semaglutide | 75 | 12 |
| Furosemide | Furosemide | 69 | 31 |
| Allopurinol | Allopurinol | 67 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 20 |
| Trazodone Hcl | Trazodone Hcl | 61 | 18 |
| Ezetimibe | Ezetimibe | 49 | 13 |
| Clonidine Hcl | Clonidine Hcl | 48 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 22 |
| Simvastatin | Simvastatin | 48 | 13 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 11 |
| Alprazolam | Alprazolam | 45 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 15 |
| Januvia | Sitagliptin Phosphate | 45 | 13 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Finasteride | Finasteride | 43 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 13 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 14 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Famotidine | Famotidine | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | 13 |
| Gavilyte-C | Peg3350/Sod Sulf,bicarb,cl/Kcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Peg 3350-Electrolyte | Sodium Chloride/Nahco3/Kcl/Peg | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 13 |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | 12 |
| Omeprazole | Omeprazole | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Lorazepam | Lorazepam | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $441.07 · 18 records | Novo Nordisk Inc | ACCRUFER, AREXVY, CONTRAVE, Dexcom G6 Transmitter, Dynasplint, INSPIRE, JARDIANCE, MOUNJARO, Ozempic, Repatha, Saxenda, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error